A single but durable stable disease sends the microcap's stock up 730%.
ApexOnco Front Page
Recent articles
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
The FDA throws out the company’s second attempt at an accelerated approval.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.